Recent meta-analyses have helped to demonstrate the benefits of SGLT2 inhibitionin HFpEF, mainly due to a reduced incidence of HF hospitalization as well as inthe composite outcome of cardiovascular death or HF hospitalization with the useof SGLT2 inhibitors [37, 38, 39]. This evidence concerns the gene SLC5A2 and hydrops fetalis.